Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
Endometrial carcinosarcomaGiorgio Bogani, Bradley J. Monk, Robert L. Coleman et al.|International Journal of Gynecological Cancer|2022Cited by 95
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P. Blagden, Andrew R. Clamp, Adrian Cook et al.|The Lancet Oncology|2020Cited by 37
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, David S.P. Tan, Tuan Zea Tan et al.|British Journal of Cancer|2025Cited by 2
PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)David S.P. Tan, Line Bjørge, Tuan Zea Tan et al.|International Journal of Gynecological Cancer|2023Cited by 1